NorthStrive Biosciences completed a preclinical study of EL-32, an engineered probiotic aimed at preserving muscle during GLP-1 weight loss therapy with semaglutide. The study in obese mice found that high-dose EL-32 combined with semaglutide led to greater lean mass and improved glucose response compared to semaglutide alone, though benefits were dose-specific and not consistently additive. EL-32 alone showed limited effects. NorthStrive plans a follow-up study using lower semaglutide doses to better assess muscle preservation, with results expected in early 2027. This research targets the unmet need for therapies that maintain muscle during obesity treatment with GLP-1 drugs.
NorthStrive Biosciences' EL-32 preclinical study on muscle preservation during semaglutide therapy is the focus here. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: Of 150 priced health-sector US stocks, 94 rose and 48 fell. Notable movers include BDX at USD 194.84 with a 6.86% decline and 100% sell order activity, IOVA at USD 9.20 gaining 5.75% with a balanced buy-sell order split, and ALMS at USD 6.20 down 5.34%.
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
ACM Research reported a 37% year-over-year revenue increase to $367.7 million in Q3 2026, driven by strong demand in electrochemical plating (ECP) and advanced packaging technologies. The company is expanding manufacturing capacity and global sales e...
Purple has renewed its partnership with Lucid Motors to continue providing WiFi services across Lucid's operations in Riyadh. This renewal ensures that both staff and visitors have secure and easy internet access, supporting Lucid's growing presence ...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed public dealings involving the purchase and sale of 118,333 ordinary shares each on November 4, 2026. The transactions were conducted within a price range of 295 to 304 per share. Ther...
